Merck has submitted Keytruda combination for FDA approval

Merck & Co. Inc. MRK, +0.10% said early Monday that it has submitted a supplemental application with the Food and Drug Administration for the cancer drug Keytruda in combination with chemotherapy, a combination that recently showed impressive results in a late-stage advanced lung cancer clinical trial.